Small molecule inhibitors of alpha-synuclein filament assembly - PubMed (original) (raw)
. 2006 May 16;45(19):6085-94.
doi: 10.1021/bi0600749.
Affiliations
- PMID: 16681381
- DOI: 10.1021/bi0600749
Small molecule inhibitors of alpha-synuclein filament assembly
Masami Masuda et al. Biochemistry. 2006.
Abstract
Alpha-synuclein is the major component of the filamentous inclusions that constitute defining characteristics of Parkinson's disease and other alpha-synucleinopathies. Here we have tested 79 compounds belonging to 12 different chemical classes for their ability to inhibit the assembly of alpha-synuclein into filaments in vitro. Several polyphenols, phenothiazines, porphyrins, polyene macrolides, and Congo red and its derivatives, BSB and FSB, inhibited alpha-synuclein filament assembly with IC(50) values in the low micromolar range. Many compounds that inhibited alpha-synuclein assembly were also found to inhibit the formation of Abeta and tau filaments. Biochemical analysis revealed the formation of soluble oligomeric alpha-synuclein in the presence of inhibitory compounds, suggesting that this may be the mechanism by which filament formation is inhibited. Unlike alpha-synuclein filaments and protofibrils, these soluble oligomeric species did not reduce the viability of SH-SY5Y cells. These findings suggest that the soluble oligomers formed in the presence of inhibitory compounds may not be toxic to nerve cells and that these compounds may therefore have therapeutic potential for alpha-synucleinopathies and other brain amyloidoses.
Similar articles
- Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins.
Taniguchi S, Suzuki N, Masuda M, Hisanaga S, Iwatsubo T, Goedert M, Hasegawa M. Taniguchi S, et al. J Biol Chem. 2005 Mar 4;280(9):7614-23. doi: 10.1074/jbc.M408714200. Epub 2004 Dec 17. J Biol Chem. 2005. PMID: 15611092 - Characterization of inhibitor-bound alpha-synuclein dimer: role of alpha-synuclein N-terminal region in dimerization and inhibitor binding.
Yamaguchi Y, Masuda M, Sasakawa H, Nonaka T, Hanashima S, Hisanaga S, Kato K, Hasegawa M. Yamaguchi Y, et al. J Mol Biol. 2010 Jan 22;395(3):445-56. doi: 10.1016/j.jmb.2009.10.068. Epub 2009 Nov 3. J Mol Biol. 2010. PMID: 19895818 - α-Synuclein aggregation and transmission are enhanced by leucine-rich repeat kinase 2 in human neuroblastoma SH-SY5Y cells.
Kondo K, Obitsu S, Teshima R. Kondo K, et al. Biol Pharm Bull. 2011;34(7):1078-83. doi: 10.1248/bpb.34.1078. Biol Pharm Bull. 2011. PMID: 21720016 - Inhibitors of alpha-synuclein oligomerization and toxicity: a future therapeutic strategy for Parkinson's disease and related disorders.
Amer DA, Irvine GB, El-Agnaf OM. Amer DA, et al. Exp Brain Res. 2006 Aug;173(2):223-33. doi: 10.1007/s00221-006-0539-y. Epub 2006 May 30. Exp Brain Res. 2006. PMID: 16733698 Review. - Filamentous nerve cell inclusions in neurodegenerative diseases: tauopathies and alpha-synucleinopathies.
Goedert M. Goedert M. Philos Trans R Soc Lond B Biol Sci. 1999 Jun 29;354(1386):1101-18. doi: 10.1098/rstb.1999.0466. Philos Trans R Soc Lond B Biol Sci. 1999. PMID: 10434313 Free PMC article. Review.
Cited by
- Functionalization of Morin-Loaded PLGA Nanoparticles with Phenylalanine Dipeptide Targeting the Brain.
Alonso M, Barcia E, González JF, Montejo C, García-García L, Villa-Hermosilla MC, Negro S, Fraguas-Sánchez AI, Fernández-Carballido A. Alonso M, et al. Pharmaceutics. 2022 Oct 31;14(11):2348. doi: 10.3390/pharmaceutics14112348. Pharmaceutics. 2022. PMID: 36365169 Free PMC article. - Role of Different Alpha-Synuclein Strains in Synucleinopathies, Similarities with other Neurodegenerative Diseases.
Melki R. Melki R. J Parkinsons Dis. 2015;5(2):217-27. doi: 10.3233/JPD-150543. J Parkinsons Dis. 2015. PMID: 25757830 Free PMC article. Review. - NMR characterization of monomeric and oligomeric conformations of human calcitonin and its interaction with EGCG.
Huang R, Vivekanandan S, Brender JR, Abe Y, Naito A, Ramamoorthy A. Huang R, et al. J Mol Biol. 2012 Feb 10;416(1):108-20. doi: 10.1016/j.jmb.2011.12.023. Epub 2011 Dec 17. J Mol Biol. 2012. PMID: 22200484 Free PMC article. - Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's Disease.
Panza F, Solfrizzi V, Seripa D, Imbimbo BP, Lozupone M, Santamato A, Zecca C, Barulli MR, Bellomo A, Pilotto A, Daniele A, Greco A, Logroscino G. Panza F, et al. Biomed Res Int. 2016;2016:3245935. doi: 10.1155/2016/3245935. Epub 2016 Jun 26. Biomed Res Int. 2016. PMID: 27429978 Free PMC article. Review. - The clustering and spatial arrangement of beta-sheet sequence, but not order, govern alpha-synuclein fibrillogenesis.
Suk JE, Lokappa SB, Ulmer TS. Suk JE, et al. Biochemistry. 2010 Feb 23;49(7):1533-40. doi: 10.1021/bi901753h. Biochemistry. 2010. PMID: 20121219 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources